Skip to Content
Biotechnology

A life-saving gene drug could hold families hostage with a $4 million price tag

November 5, 2018

Swiss drug company Novartis has hinted that it could charge as much as $4 to $5 million for a new gene therapy, according to Reuters.

Rare disease: The gene replacement treatment, not yet approved, is for type 1 spinal muscular atrophy, a fatal inherited disease that strikes 1 in 20,000 toddlers. A single dose of the therapy appears to prevent the disease if given shortly after birth. In other words, it looks like a true cure.

Strike it rich: The gene therapy technology was spun out by Nationwide Children’s Hospital into a startup, AveXis, which tested it in a dozen or so children. Earlier this year, Novartis acquired AveXis for almost $9 billion. The deal made a few people very wealthy. It also pretty much guaranteed an eye-watering price tag.  

Pay up: Novartis hasn’t announced a final price, but according to Reuters, Dave Lennon, president of AveXis, said during a conference call that “four million dollars is a significant amount of money, but we believe this is a cost-effective point.” The previous record price for a drug was about $1 million for Glybera, also a gene therapy.

Why so much? Rare diseases are, well, really rare. And drug companies think in terms of blockbusters. The only way to turn a rare-disease treatment that’s given just once into a profit-maker is to charge ultra-high prices.

Life or death: Expect Novartis to face tough questions going forward. One critic on Twitter noted that ransoms paid to criminal gangs to release hostages are often only about $2 million. 

Deep Dive

Biotechnology

The first babies conceived with a sperm-injecting robot have been born

Meet the startups trying to engineer a desktop fertility machine.

Doctors have performed brain surgery on a fetus in one of the first operations of its kind

A baby girl who developed a life-threatening brain condition was successfully treated before she was born—and is now a healthy seven-week-old.

A brain implant changed her life. Then it was removed against her will.

Her case highlights why we need to enshrine neuro rights in law.

The FDA just approved rub-on gene therapy that helps “butterfly” children

Biotech companies are getting creative with how they deliver DNA fixes into people's bodies.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.